IGF2BP3 Overexpression Accelerates Osteoarthritis Progression by Promoting Glycolysis via m 6 A ‐Dependent Stabilization of ECM1 mRNA
Open Access
- 19 August 2026
- journal article
- research article
- Published by Wiley in The Kaohsiung Journal of Medical Sciences
- p. e70280
Abstract
N 6 ‐methyladenosine (m 6 A) plays a critical role in osteoarthritis (OA) pathogenesis. This study investigates the role of the m 6 A reader insulin‐like growth factor 2 mRNA‐binding protein 3 (IGF2BP3) in OA progression. OA models were established in vivo through destabilization of the medial meniscus (DMM) surgery in mice and in vitro by stimulating primary chondrocytes with interleukin‐1β (IL‐1β). Cartilage destruction was assessed histopathologically. Chondrocyte viability, proliferation, and apoptosis were measured by CCK‐8, EdU, and flow cytometry, respectively. Inflammatory cytokine levels, lactate, glucose, and total m 6 A were quantified using commercial kits. Expression levels of IGF2BP3, extracellular matrix protein 1 (ECM1), ECM turnover markers, and glycolysis‐related genes were analyzed by RT‐qPCR, Western blot, immunohistochemistry, and immunofluorescence. Potential m 6 A modification sites in ECM1 transcripts were predicted using the SRAMP database, and IGF2BP3‐mediated, m 6 A‐dependent regulation of ECM1 was validated through RNA immunoprecipitation (RIP), MeRIP‐qPCR, and actinomycin D decay assays. Results revealed elevated levels of IGF2BP3, ECM1, m 6 A modification, and glycolytic activity in OA cartilage and IL‐1β‐treated chondrocytes. IGF2BP3 knockdown reversed IL‐1β‐induced reductions in chondrocyte viability and proliferation, suppressed apoptosis, decreased inflammatory cytokine secretion, attenuated ECM degradation, and reduced glycolytic flux in vitro, while also mitigating cartilage damage and matrix breakdown in vivo. Mechanistically, IGF2BP3 stabilized ECM1 mRNA in an m 6 A‐dependent manner, thereby modulating ECM1 expression. Restoration of ECM1 expression abolished the chondroprotective effects of IGF2BP3 knockdown against injury, inflammation, and enhanced glycolysis. In conclusion, IGF2BP3 enhances ECM1 expression via an m 6 A‐dependent pathway, thereby promoting glycolysis and exacerbating OA progression.Keywords
Funding Information
- National Natural Science Foundation of China (82072408)
This publication has 37 references indexed in Scilit:
- FOXM1-activated IGF2BP3 promotes cell malignant phenotypes and M2 macrophage polarization in hepatocellular carcinoma by inhibiting ferroptosis via stabilizing RRM2 mRNA in an m6A-dependent mannerMolecular and Cellular Biochemistry, 2024
- Lactylation‐Driven IGF2BP3‐Mediated Serine Metabolism Reprogramming and RNA m6A—Modification Promotes Lenvatinib Resistance in HCCAdvanced Science, 2024
- IGF2BPs as novel m6A readers: Diverse roles in regulating cancer cell biological functions, hypoxia adaptation, metabolism, and immunosuppressive tumor microenvironmentGenes & Diseases, 2024
- Targeting YAP1‐regulated Glycolysis in Fibroblast‐Like Synoviocytes Impairs Macrophage Infiltration to Ameliorate Diabetic Osteoarthritis ProgressionAdvanced Science, 2023
- Downregulation of extracellular matrix protein 1 effectively ameliorates osteoarthritis progression in vivoInternational Immunopharmacology, 2023
- Hsa_circ_0004287 inhibits macrophage-mediated inflammation in an N6-methyladenosine–dependent manner in atopic dermatitis and psoriasisJournal of Allergy and Clinical Immunology, 2022
- RPL38 knockdown inhibits the inflammation and apoptosis in chondrocytes through regulating METTL3-mediated SOCS2 m6A modification in osteoarthritisInflammation Research, 2022
- The role of metabolism in chondrocyte dysfunction and the progression of osteoarthritisAgeing Research Reviews, 2021
- Modulation of circRNA Metabolism by m6A ModificationCell Reports, 2020
- Future therapeutics for osteoarthritisBone, 2012